Crucell and NIH Extend Ebola Vaccine Agreement

Dutch biotechnology company Crucell N.V. announced that it has extended its Cooperative Research and Development Agreement (CRADA) with the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), for the development of vaccines to protect against Ebola, Marburg and Lassa infections.

PrimeZone (http://www.primezone.com/newsroom/news_releases.mhtml?d=74668)